Mahamaya Lifesciences Limited reported a 29% year-on-year increase in profit after tax (PAT) to ₹1,652.33 lakh for the fiscal year ended March 31, 2026, driven by a 24.5% rise in revenue from operations to ₹32,887.30 lakh. The agrochemical company's EBITDA surged 32.06% to ₹3,425.88 lakh, with margins expanding by 60 basis points to 10.42%, reflecting improved operational efficiencies despite significant accounting adjustments related to its recent listing.

Financial Performance

The company's revenue growth was supported by strong performance across both halves of the fiscal year. H2 FY26 revenue reached ₹16,580.93 lakh, slightly higher than H1 FY26's ₹16,306.37 lakh. Profitability was impacted by approximately ₹411 lakh in adjustments, including an unrealized forex loss of ₹264.16 lakh, an exchange difference of ₹125.25 lakh, and listing-related expenses of ₹21.57 lakh. The diluted earnings per share (EPS) for FY26 stood at ₹8.33, compared to ₹7.52 in the previous year.

Consolidated Results

The consolidated financial results include the performance of its subsidiary, Mahamaya Lifesciences (FZE), based in the UAE. Total income for the year stood at ₹33,003.23 lakh. The board approved the audited standalone and consolidated financial results during a meeting on May 25, 2026.

Key Financial Metrics

The following table summarizes the consolidated financial performance for FY26:

Operational Outlook

Mr. Prashant Krishnamurthy, Executive Director, highlighted the company's focus on expanding its sustainable and biological crop care portfolio. The company is strengthening its presence in domestic and export markets, leveraging its modern Dahej facility for large-scale production and R&D innovation to ensure regulatory compliance under BIS and FAO standards.

Mahamaya Lifesciences Limited has officially informed BSE Limited about its exemption from corporate governance compliance requirements under SEBI regulations. The company submitted a formal communication dated April 15, 2026, to BSE's Listing Compliance Department regarding this regulatory exemption.

Regulatory Exemption Details

The company has invoked the non-applicability criteria provided under Regulation 15(2)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This exemption is specifically available to companies whose equity shares are listed on the BSE SME Platform.

Impact on Compliance Requirements

Due to this exemption, Mahamaya Lifesciences Limited is not required to file corporate governance reports as mandated under Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The exemption covers:

• Quarterly corporate governance reports
• Half-yearly corporate governance reports
• Yearly corporate governance reports

Company Information

Mahamaya Lifesciences Limited, formerly known as Mahamaya Lifesciences Pvt. Ltd., operates from its registered office located at Spaze ITech Park, Sector-49, Sohna Road, Gurugram, Haryana. The company holds CIN L24233DL2002PLC115261 and maintains ISO 9001:2015 certification.

Official Communication

The formal notification was signed by Shilpi Bhardwaj, Company Secretary & Compliance Officer (Membership No.: A24444), and submitted to BSE Limited for official records. The communication ensures transparency regarding the company's compliance status under current SEBI regulations for SME-listed entities.